<DOC>
	<DOCNO>NCT02511379</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Systane® Balance follow 90 day QID ( 4 times/day ) dosing among Indian subject dry eye . This study conduct India .</brief_summary>
	<brief_title>Clinical Evaluation Systane® Balance Dry Eye Subjects</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Sign inform consent willing able attend study visit ; Dry eye eye diagnosed ophthalmologist ; Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant breastfeeding ; Any medical condition ( systemic ophthalmic ) may preclude safe administration test article safe participation study ; Ocular surgery ocular trauma require medical pharmacological treatment within 1 year Screening ; Use topical ocular prescription nonprescription medication , RESTASIS topical ocular steroid within 14 day Screening ; Use artificial tears/gels/lubricants/rewetting drop within 4 hour Screening ; Contact lens wear within 1 week Screening and/or unwillingness discontinue contact lens wear duration study ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>